Your browser doesn't support javascript.
loading
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges.
Alhallak, Kinan; Sun, Jennifer; Jeske, Amanda; Park, Chaelee; Yavner, Jessica; Bash, Hannah; Lubben, Berit; Adebayo, Ola; Khaskiah, Ayah; Azab, Abdel Kareem.
Affiliation
  • Alhallak K; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Sun J; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
  • Jeske A; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Park C; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
  • Yavner J; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Bash H; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
  • Lubben B; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Adebayo O; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Khaskiah A; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
  • Azab AK; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Cancers (Basel) ; 13(12)2021 Jun 08.
Article de En | MEDLINE | ID: mdl-34201007
ABSTRACT
MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancers (Basel) Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancers (Basel) Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique